Answers are grounded in this paper and cite their sources.
The comparative real-world effectiveness of extended-release (Life Cycle Pharma tacrolimus [LCPT]) vs immediate-release (IR) tacrolimus formulations in deceased-donor kidney transplantation remains incompletely characterized. We conducted a national retrospective cohort study of adult deceased-donor kidney transplant (DDKT) recipients in the Organ Procurement and Transplantation Network/United Network for Organ Sharing registry (January 1, 2018-June 30, 2023) discharged on tacrolimus plus mycophenolate. Multiorgan and living-donor transplants, and recipients who switched formulations during the index hospitalization, were excluded. Exposure was the tacrolimus formulation at discharge (IR-brand, IR-generic, or LCPT). The prespecified primary outcome was all-cause graft failure (ACGF), evaluated using inverse probability of treatment weighting-adjusted Cox models. Among 79 833 recipients, LCPT (n = 11 581) was associated with a lower adjusted hazard of ACGF than IR-brand tacrolimus (hazard ratio [HR], 0.877; 95% confidence interval [CI], 0.797-0.965), whereas IR-generic and IR-brand did not differ (HR, 0.939; 95% CI, 0.868-1.016). The association was consistent in a sensitivity analysis restricted to centers prescribing all 3 formulations (HR, 0.872; 95% CI, 0.789-0.963) and in a propensity-score-matched analysis comparing LCPT with combined IR tacrolimus (HR, 0.913; 95% CI, 0.836-0.998). In this national deceased-donor kidney transplant cohort, LCPT was associated with a modestly lower adjusted risk of ACGF relative to IR tacrolimus.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: